Impact of HER2-low and HER2-zero status on outcomes: A multicenter propensity-score matched study

被引：0
|
作者：
Cha, C. D. [1 ]
Kim, K. E. [2 ]
Kim, J. [3 ]
Um, E. [4 ]
Choi, N. [5 ]
Lee, J. [2 ]
Gwak, G. [3 ]
Kim, J. I. [4 ]
Chung, M. S. [1 ]
机构：
[1] Hanyang Univ, Coll Med, Surg, Seoul, South Korea
[2] Inje Univ, Coll Med, Surg, Haeundae Paik Hosp, Busan, South Korea
[3] Inje Univ, Sanggye Paik Hosp, Sch Med, Surg, Seoul, South Korea
[4] Inje Univ, Ilsan Paik Hosp, Ilsan, South Korea
[5] Hanyang Univ, Med Res Collaborating Ctr, Seoul, South Korea
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.104089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P248
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women
    Zagami, Paola
    Abdou, Yara
    Wardell, Alexis Caroline
    Deal, Allison Mary
    Wheless, Amy
    Dees, Elizabeth Claire
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] HER2-LOW POSITIVE AND HER2-ZERO BREAST CANCERS ARE CLINICALLY DISTINCT
    不详
    CANCER DISCOVERY, 2021, 11 (09) : 2124 - 2124
  • [3] The clinicopathological and prognostic significance of HER2-low breast cancer: A comparative analysis between HER2-low and HER2-zero subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CANCER RESEARCH, 2024, 84 (09)
  • [4] The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CLINICAL BREAST CANCER, 2024, 24 (05) : 431 - 438
  • [5] A Comparison of the Biological Profiles of HER2-Low, HER2-Amplified and HER2-Zero Breast Cancers
    Farshid, Gelareh
    Pradhan, Malcolm
    LABORATORY INVESTIGATION, 2023, 103 (03) : S127 - S129
  • [6] Comparison of Clinicopathological Features and Survival Outcomes Associated with HER2-Zero and HER2-Low Breast Cancers: A retrospective, Observational Study
    Ucar, Mahmut
    Yilmaz, Mukaddes
    Erdis, Eda
    Yucel, Birsen
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2024, 34 (04): : 220 - 230
  • [7] Racial disparity in the clinical outcomes of HER2-low and HER2-zero early-stage breast cancer.
    Gandhi, Shipra
    Catalfamo, Kayla
    Attwood, Kristopher
    Kapoor, Ankita
    Jatwani, Karan
    Roy, Arya Mariam
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers
    Huang, Xu
    Wu, Lei
    Liu, Yu
    Xu, Zeyan
    Liu, Chunling
    Liu, Zaiyi
    Liang, Changhong
    BRITISH JOURNAL OF RADIOLOGY, 2024, 97 (1161):
  • [9] Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer
    Yin, Liang
    Zhang, Yun
    Wei, Xi
    Shaibu, Zakari
    Xiang, Lingling
    Wu, Ting
    Zhang, Qing
    Qin, Rong
    Shan, Xiuhong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysis
    Sanchez Bayona, R.
    Luna, A. M.
    Tolosa, P.
    Sanchez De Torre, A.
    Castelo, A.
    Marin, M.
    Garcia, C.
    Boni, V.
    Bernal Hertfelder, E.
    Vega, E.
    Rojas, B.
    Bratos, R.
    Martinez, M.
    Diaz Bermejo, A. J.
    Lema, L.
    Manso, L.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S29 - S30
12345